NCT02601976View on ClinicalTrials.gov

Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population

PHASE4CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2014

Conditions
Hepatitis C
Interventions
DRUG

Peginterferon alfa-2a

PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.

DRUG

Ribavirin

Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Sponsors

Lead Sponsor

Getz Pharma

Collaborators (1)

Dimension Research
All Listed Sponsors
collaborator

Dimension Research

INDUSTRY

lead

Getz Pharma

INDUSTRY